ArticlePharmacoEconomics - open2019

Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States.

Jill A Bell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.